Toyota|$18.00 (¥2,881)+1.30%▲ (in JPY terms)
Sony|$22.61 (¥3,619)-1.36%▼ (in JPY terms)
SoftBank|$51.96 (¥8,315)-3.67%▼ (in JPY terms)
MUFG|$19.60 (¥3,137)+2.99%▲ (in JPY terms)
Keyence|$503.84 (¥80,630)+2.92%▲ (in JPY terms)
Nintendo|$46.60 (¥7,457)+0.42%▲ (in JPY terms)
NTT|$0.92 (¥148)-0.07%▼ (in JPY terms)
Takeda|$29.67 (¥4,748)-2.10%▼ (in JPY terms)
Tokyo Electron|$380.55 (¥60,900)+13.39%▲ (in JPY terms)
Recruit|$68.24 (¥10,920)+0.69%▲ (in JPY terms)
ITOCHU|$11.61 (¥1,859)+0.05%▲ (in JPY terms)
Honda|$9.35 (¥1,497)+7.89%▲ (in JPY terms)
Shin-Etsu|$48.78 (¥7,806)+4.46%▲ (in JPY terms)
Tokio Marine|$44.35 (¥7,098)+0.74%▲ (in JPY terms)
Fast Retailing|$490.03 (¥78,420)-1.58%▼ (in JPY terms)
Toyota|$18.00 (¥2,881)+1.30%▲ (in JPY terms)
Sony|$22.61 (¥3,619)-1.36%▼ (in JPY terms)
SoftBank|$51.96 (¥8,315)-3.67%▼ (in JPY terms)
MUFG|$19.60 (¥3,137)+2.99%▲ (in JPY terms)
Keyence|$503.84 (¥80,630)+2.92%▲ (in JPY terms)
Nintendo|$46.60 (¥7,457)+0.42%▲ (in JPY terms)
NTT|$0.92 (¥148)-0.07%▼ (in JPY terms)
Takeda|$29.67 (¥4,748)-2.10%▼ (in JPY terms)
Tokyo Electron|$380.55 (¥60,900)+13.39%▲ (in JPY terms)
Recruit|$68.24 (¥10,920)+0.69%▲ (in JPY terms)
ITOCHU|$11.61 (¥1,859)+0.05%▲ (in JPY terms)
Honda|$9.35 (¥1,497)+7.89%▲ (in JPY terms)
Shin-Etsu|$48.78 (¥7,806)+4.46%▲ (in JPY terms)
Tokio Marine|$44.35 (¥7,098)+0.74%▲ (in JPY terms)
Fast Retailing|$490.03 (¥78,420)-1.58%▼ (in JPY terms)

SUMITOMO CHEMICAL COMPANY,LIMITED “We have released a YouTube video titled "A Close Look at Our Employees' Challenges! ~[A Day in the Life] Taking on Diseases That Couldn't Be Cured with Conventional Medicines! The Challenges of Oligonucleotide Department Members Supporting Cutting-Edge Pharmaceutical Development~".”

SUMITOMO CHEMICAL COMPANY,LIMITED “We have released a YouTube video titled "A Close Look at Our Employees' Challenges! ~[A Day in the Life] Taking on Diseases That Couldn't Be Cured with Conventional Medicines! The Challenges of Oligonucleotide Department Members Supporting Cutting-Edge Pharmaceutical Development~".”

AI-Generated Summary

Sumitomo Chemical is highlighting its oligonucleotide drug development capabilities through employee-focused content, signaling management’s commitment to positioning the company as an innovator in next-generation pharmaceuticals for previously intractable diseases. This marketing initiative suggests the company views its oligonucleotide platform as a material growth driver and is investing in employer branding to attract talent in this strategically important research area.

This summary is AI-generated based on the release title and may not reflect the full content of the original document.

コメントする